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Identity 
Note: Anaplastic (undifferentiated) carcinoma of the 
thyroid gland is a highly malignant tumor composed in 
part or wholly by undifferentiated malignant cells. 
Clinics and pathology 
Epidemiology 
Anaplastic (undifferentiated) carcinoma of the thyroid 
gland is uncommon, accounting for less than 5% of all 
cases of thyroid carcinoma. The average age at 
diagnosis was 66.5 years, with a female to male ratio of 
3.1:1 in one study of 70 cases. 
Clinics 
Most patients are euthyroid with a history of a rapidly 
enlarging neck mass. Sometimes, the tumor presents as 
a new-onset thyroid enlargement in a patient with 
longstanding thyroid nodule(s) or as the recurrence of a 
well-differentiated thyroid carcinoma. Tumor 
infiltration of surrounding structures results in 
secondary symptoms (dyspnea, dysphonia, dysphagia). 
Pathology 
Tumors are poorly defined, fleshy masses with areas of 
necrosis and hemorrhage. Microscopically they are 
composed of anaplastic cells with marked cytologic 
atypia and high mitotic activity. Tumor necrosis and 
vascular invasion are common. About one-third of 
cases of anaplastic thyroid carcinoma (ATC) have 
coexisting areas of well-differentiated thyroid 
carcinoma, supporting the hypothesis that ATC arises 
from well-differentiated thyroid carcinoma. 
Histologic patterns include spindle, giant and squamoid 
cell types. Other patterns (e.g. angiomatoid, 
carcinosarcoma, lymphoepithelioma-like, 
adenosquamous) have been described. Undifferentiated 
(anaplastic) carcinoma of the thyroid must be 
differentiated from other high grade tumors with 
similar microscopic appearance originating from 
adjacent structures in the neck (e.g. larynx). Sometimes 
this distinction is only possible on clinical/anatomical 
grounds. 
Immunohistochemically, undifferentiated thyroid 
carcinoma is generally negative for thyroglobulin and 
calcitonin. Pankeratin and epithelial membrane antigen 
(EMA) are positive in about one-half and one-third of 
cases respectively. Vimentin is positive in about 90%, 
and epithelial membrane antigen is positive in about 
30% of cases. Thyroid transcription factor-1 (TTF-1) 
staining is present in 0-50% of cases. Although 
immunostaining is negative for muscle-specific actin, 
Factor VIII-related antigen, and desmin, these markers 
can differentiate ATC from some soft tissue sarcomas 
with which they can be confused. 
Treatment 
No effective treatment modalities are currently 
available. A few patients with resectable disease have 
been reported to have long-term survival with 
aggressive multimodal therapy that included surgery, 
radiation, and chemotherapy. Current clinical practice 
emphasizes the use of multimodal therapy to achieve 
local disease control and stabilization of airway 
patency. Radiotherapy may be hyperfractionated and in 
combination with chemotherapy. Chemotherapy is 
usually doxorubicin-based or taxane-based 
combinations. Preclinical studies using human ATC  
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Anaplastic (undifferentiated) thyroid carcinoma is a highly malignant tumor composed by undifferentiated malignant cells. The inset in 
the left lower corner shows a magnified view of a cell in metaphase of mitosis. 
 
cell lines show promise that new effective 
combinations including novel drugs will be found in 
the future. 
Prognosis 
Anaplastic (undifferentiated) carcinomas are highly 
aggressive neoplasms that are usually widely invasive 
at presentation. Regional and distant metastases are 
common, and about 75% of patients have distant 
metastasis in the course of their disease. Most patients 
die within 1 year of the diagnosis with a median 
survival of 3 to 6 months. The 5-year survival rate is 
around 5%, and the surviving cases are typically small 




Anaplastic (undifferentiated) carcinoma represents not 
only morphologically but also in terms of somatic 
genetic alterations the extreme malignant form of 
thyroid cancer and as such it is characterized by 
complex chromosomal alterations. DNA aneuploidy is 
present in over 65% of the tumors. 
Cytogenetics molecular 
LOH: Allelic loss has been identified at 1q (40%), 9p 
(58%), 11p (33%), 11q (33%), 17p (44%), 17q (43%), 
19p (36%), 22q (38%). 
CGH: DNA unbalance can be demonstrated at a variety 
of chromosomal loci in 80% of undifferentiated 
carcinomas with a median number of chromosomal 
losses or gains of 10 per case with abnormal CGH 
profile. Gains were more common than DNA losses. 
Loss of chromosomal DNA was identified at 1p, 2q, 
4q, 5q, 6q, 8p, 13q, 22q. Specific chromosomal DNA 
alterations (i.e. 3p13-14+, 5q11-31-, 11q13+) may be 
associated with the transition from more differentiated 
phenotypes to ATC. 
CGH shows frequent gain of 20q, including the 
UBCH10 gene in 20q13.12, which may also be 
associated with progression of differentiated thyroid 
cancers to ATC. 
Using microarray-based CGH with further fluorescence 
in situ hybridization (FISH) analysis, the MAP kinase 
phosphatase-8 (DUSP26) gene, which codes for a 
phosphatase that inhibits p38-mediated apoptosis, is 
shown to be amplified in ATC. 
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Genes involved and Proteins 
Note: The genetic mechanisms involved with the 
development of anaplastic thyroid cancer are complex. 
Mutational inactivation of p53 has been identified in 
70-80% of anaplastic carcinomas while H-Ras, K-Ras, 
or N-Ras activating mutations are present in 
approximately 50% of the cases. BRAF V600E 
mutation is found in 20% to 25% of cases. PTEN 
mutations are present in 6%. PIK3CA kinase domain 
mutations are found in 14%. PIK3CA gene copy 
amplification is present in 39%. 
Aberrant Wnt/beta-Catenin signaling appears to be a 
distinctive feature of ATC since stabilizing mutations 
and/or aberrant beta-Catenin nuclear localization are 
present in 80% of ATC. beta-Catenin nuclear 
localization is accompanied by its cellular 
redistribution with marked decrease of the beta-Catenin 
membrane bound fraction. 
ATC are characterized by increased cell replication and 
high Ki67/Mib1 proliferation index, loss of the 
apoptotic protein bcl-2 and of Fas and its ligand 
(usually highly expressed in well differentiated thyroid 
tumors), by an increase in the proapoptotic protein Bax, 
by Cyclin D1 over-expression and conversely by a fall 
in the CDK inhibitor p27. Transmembrane protein 34 
(TMEM34) is down-regulated in ATC. It is not clear 
whether these changes represent the cause or (more 
likely) the effect of dysregulated cell differentiation 
and growth in ATC. 
Immunohistochemical staining of a tissue microarray of 
32 cases of ATC showed the following: beta-catenin 
(positive in 41% of the cases), aurora A (41%), cyclin 
E (67%), cyclin D1 (77%), and EGFR (84%). 
Thyroglobulin, Bcl-2, MIB-1, E-cadherin, and p53, 
beta-catenin, topoisomerase II-alpha, and vascular 
endothelial growth factor are observed to change 
during progression from differentiated thyroid cancer to 
ATC. 
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